# Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids

> **NCT02977286** · PHASE4 · TERMINATED · sponsor: **Tufts Medical Center** · enrollment: 12 (actual)

## Conditions studied

- Constipation

## Interventions

- **DRUG:** Naloxegol Oral Tablet
- **DRUG:** Placebo Oral Tablet
- **DRUG:** Docusate Sodium 100 Mg oral capsule [Colace]
- **DRUG:** Senna 217 Mg Oral Tablet
- **DRUG:** Polyethylene Glycols
- **DRUG:** Bisacodyl 10 mg Suppository
- **DRUG:** Magnesium Citrate Oral Liquid Product
- **DRUG:** Methylnaltrexone

## Key facts

- **NCT ID:** NCT02977286
- **Lead sponsor:** Tufts Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-01
- **Primary completion:** 2019-10-09
- **Final completion:** 2019-10-09
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Poor enrollment
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02977286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02977286, "Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02977286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*